GEN Exclusives

More »

GEN News Highlights

More »
Dec 27, 2012

Soligenix Regains Rights to Ill-Fated Oral BDP

  • Soligenix has regained the North American and European commercial rights to orBec (oral beclomethasone 17.21-dipropionate) from Sigma-Tau Pharmaceuticals. Soligenix is now free to commercialize or enter into commercialization agreements for its oral BDP suite of products with other parties without limitation.

    According to Soligenix, orBec is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. Oral BDP has been marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma.

    In July 2011, Sigma-Tau inked a commercialization deal for orBec that included a $5 million upfront payment to Soligenix. The company also agreed to pay $11 million in potential milestones to Soligenix.

    Following the Sigma-Tau deal, Soligenix reported a series of disappointing clinical trial results for orBec.

    In October of this year, Sigma-Tau Pharmaceuticals appointed Jeff Hackman as its new vice president of commercial operations.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?